

Clinical Presentations of Monoclonal Gammopathy Cases in A Tertiary Care Referral Centre of Bangladesh

Monwar Tarek¹, Latifa Rahman², Md. Manirul Islam³, Nilufa Parvin⁴

¹Classified Specialist in Pathology, Armed Forces Institute of Pathology (AFIP), Dhaka, Bangladesh; ²Associate Professor, Department of Community Medicine, Armed Forces Medical College, Dhaka, Bangladesh; ³Assistant Professor, Department of Haematology, Dhaka Medical College, Dhaka, Bangladesh; ⁴Assistant Professor, Department of Obstetrics & Gynecology, Sir Salimullah Medical College, Dhaka, Bangladesh

[Received: 12 November 2019; Accepted: 2 December 2019; Published: 1 January 2020]

Abstract

Background: Monoclonal gammopathy are haematologic disorder characterized by abnormal production of one or more immunoglobulin clone. Accurate detection and quantitation of monoclonal immunoglobulins is important for diagnosis and management of monoclonal gammopathies. There are very few studies related to monoclonal gammopathy in Bangladesh. This study was aimed to observe the clinical profile and immunoglobulin pattern of monoclonal gammopathy cases in a tertiary care referral center. **Objective:** This study was aimed to observe the clinical profile and immunoglobulin pattern of monoclonal gammopathy cases in a tertiary care referral center. **Methodology:** This cross sectional study was conducted in the Department of Haematology, Armed Forces Institute of Pathology (AFIP), Dhaka Cantonment, Dhaka. Study Period was July 2014 to Dec 2014. Patients with the age between 40 to 70 years of both sexes who were diagnosed as cases of monoclonal gammopathies was selected as study population. All patients were interviewed by using standard questionnaire and general medical condition of the patients was evaluated through history taking, clinical examination and laboratory investigations. Bone marrow microscopic examination, serum protein electrophoresis, immunofixation electrophoresis (IFE), skeletal survey and relevant biochemical tests including serum creatinine, calcium, albumin and urinary BJP were performed. Protein electrophoresis of the samples was performed by automated capillary electrophoresis machine. **Results:** A total of 30 cases were recruited for this study. Out of 30 monoclonal gammopathy cases, majority of cases 17(56.7%) were between 60 to 70 years age group. Mean age was 57.13(±9.66) years. Male were predominant 19(63.0%) and Male female ratio was 1.72:1. Among the patients, low backache and pallor was common in majority (80%) of the cases, while fatigue and fever were present in 73.3% and 70.0% cases respectively. Among the patients, 7(23.3%) were hypertensive, 6(20.0%) were diabetic, 3(10.0%) patients were suffering from CKD with hypertension, 3(10.0%) had bronchial asthma, 1(3.3%) was with hypertension and Diabetes Mellitus. Depending on different laboratory findings, among all the 30 cases, 21(70%) cases were diagnosed as multiple myeloma, 5(16.6%) cases were MGUS and 2(6.7%) cases were Smouldering multiple myeloma and kappa light chain multiple myeloma each. Among the multiple myeloma cases, 11(36.6%) cases had IgG Kappa monoclonal gammopathy and 6(20.0%) cases had IgG Lambda monoclonal gammopathy. **Conclusion:** Monoclonal gammopathy occurs predominantly in male population at around sixth decade and mostly are presented with fatigue and bone pain. Majority of the patients suffered from multiple myeloma. [Journal of National Institute of Neurosciences Bangladesh, 2020;6(1): 19-23]

Keywords: : Serum; Protein Electrophoresis; Immunofixation Electrophoresis (IFE); Bence Jones protein; Multiple myeloma; M Protein

Correspondence: Lt. Col. Dr. Monwar Tarek, Classified Specialist in Pathology, Armed Forces Institute of Pathology (AFIP), Dhaka Cantonment, Dhaka, Bangladesh; Cell no.: +8801715010064; Email: tarekmonwar70@gmail.com

Conflict of interest: There is no financial conflict of interest relevant to this paper to disclose.

Funding agency: This research project was not funded by any group or any institution.

Contribution to authors: Tarek M, Rahman L have contributed from the protocol preparation, data collection up to report writing. Manuscript writing has been performed by Islam MM, Parvin N. Tarek M has revised the manuscript.

How to cite this article: Tarek M, Rahman L, Islam MM, Parvin N. Clinical Presentations of Monoclonal Gammopathy Cases in A Tertiary Care Referral Centre of Bangladesh. J Natl Inst Neurosci Bangladesh, 2020;6(1): 19-23

Copyright: ©2020. Tarek et al. Published by Journal of National Institute of Neurosciences Bangladesh. This article is published under the Creative Commons CC BY-NC License (<https://creativecommons.org/licenses/by-nc/4.0/>). This license permits use, distribution and reproduction in any medium, provided the original work is properly cited, and is not used for commercial purposes.

Introduction

The presence of abnormal monoclonal proteins, which is referred to as monoclonal gammopathy, is a frequent, characteristic feature of plasma cell dyscrasias. Monoclonal gammopathy are haematologic disorder characterized by abnormal production of one or more immunoglobulin clone. Accurate detection and quantitation of monoclonal immunoglobulins is important for diagnosis and management of monoclonal gammopathies^{1,2}. They range from asymptomatic benign disorder such as monoclonal gammopathy of undetermined significance (MGUS) to malignant plasma cell and lymphoid disorder, including multiple myeloma and Waldenstrommacroglobulinemia³.

In particular, monoclonal immunoglobulin can be used for screening, monitoring and monitoring disease progression in MGUS. Multiple myeloma accounts for 1% of malignant disorder, but is the most common malignant plasma cell dyscrasia and ranks second among primary haematological malignancies, with a peak incidence in the 7th decade. The incidence of multiple myeloma (MM) is increasing rapidly in Asian countries^{4,5}. Approximately 30.0% of monoclonal gammopathy patients (including patients with light chain myeloma, primary AL amyloidosis, non-secretory myeloma, and light chain deposition disease) produce free light chains (FLC) as the only monoclonal component⁶.

The monoclonal protein is usually detected as a discrete band in the γ or β region in serum or urine protein electrophoresis (M spike). The nature of the monoclonal protein is then characterized and confirmed by an immunofixation electrophoresis (IFE). There are very few studies related to monoclonal gammopathy in Bangladesh. Therefore, this study was aimed to observe the clinical profile and immunoglobulin pattern of monoclonal gammopathy cases in a tertiary care referral center.

Methodology

This cross sectional study was conducted in the Department of Haematology at Armed Forces Institute of Pathology (AFIP), Dhaka Cantonment, Dhaka, Bangladesh. Study Period was July 2014 to Dec 2014. Patients aged between 40 to 70 years old with both sexes who were diagnosed as cases of monoclonal gammopathies were selected as study population. No cases of plasma cell dyscrasia with other malignancy were included in the study. All patients were interviewed by using standard questionnaire which was containing socio-demographic and relevant information. General medical condition of the patients was evaluated through

history taking, clinical examination and laboratory investigations. Blood sample and bone marrow aspiration were collected from the patient. Bone marrow microscopic examination, serum protein electrophoresis, immunofixation electrophoresis (IFE), skeletal survey and relevant biochemical tests including serum creatinine, calcium, albumin and urinary Ben-Johns Protein (BJP) were performed. Protein electrophoresis of the specimens was performed by automated capillary electrophoresis machine (Capiflex-2) which was identified the various protein bands and depicted as a graph. The M band was usually found in the gamma globulin region; however, in a few cases it was identified in the beta region also. The machine identified the M protein both qualitatively and quantitatively. Immunofixation electrophoresis (IFE) separated the serum protein by electrophoresis followed by treatment of the protein with specific antiserum against IgG, IgA, IgM, IgD, IgE, kappa and lambda. If the M protein was present, a precipitated band was formed. The gel was washed with saline to extract all unprecipitated protein which was then stained followed by de-colourization and dried.

Results

A total number of 30 cases were recruited for this study. Among 30 monoclonal gammopathy cases, 19 (63.0%) were male and 11 (37.0%) were female. Majority of the patients belonged to the age group of 60 to 70 years. The haemoglobin concentration was < 9 gm/dl in majority of the cases (80%). It was revealed in blood film that 50 % patients were suffering from anaemia of chronic disorder. In bone marrow microscopy examination, majority (73.3%) of the patients were found suggestive of multiple myeloma. Serum protein electrophoresis test revealed that majority (80%) of the patients were having monoclonal band (M band) and 20% had a normal findings. In IFE, 80% of the samples were positive for IgG monoclonal protein while IgA, IgM and light chain kappa monoclonal protein were 6.7 % for each group (Table 1).

The serum protein electrophoresis according to different immunoglobulin pattern was recorded. In IgG Kappa monoclonal gammopathy monoclonal protein (M band) 93.3% cases and then normal finding 6.7% cases. In IgG lambda monoclonal gammopathy monoclonal protein (M band) was in 66.7% cases and normal finding was in 33.3% cases. IgM Kappa monoclonal gammopathy Monoclonal protein (M band) 100.0%. In IgA Kappa monoclonal gammopathy

monoclonal protein (M band) was found in 100% cases. In light change kappa monoclonal gammopathy normal finding was in 100.0%cases (Table 2).

Table 1: Demographic Data and Laboratory Findings of Monoclonal Gammopathy Cases (n= 30)

Variables	Frequency	Percent
Age Group		
• 40 to 49 Years	07	23.3
• 50 to 59 Years	06	20.0
• 60 to 70 Years	17	56.7
Mean±SD (Range)	57.13±9.66(40-70 years)	
Gender		
• Male	19	63.0
• Female	11	37.0
Hb concentration		
• Below 9 gm/dL	18	60.0
• Between 9 gm/dL to lower normal range	6	20.0
• Within Normal reference	6	20.0
Peripheral Blood Film		
• Anaemia of chronic disorder	15	50.0
• Microcytic hypochromic with high ESR	05	16.7
• Neutrophil leucocytosis with high ESR	04	13.3
• None specific findings	03	10.0
• Leuco-erythro-blastic blood picture	03	10.0
Bone Marrow Study		
• Suggestive of Multiple myeloma (bone marrow plasma cell >20%)	22	73.3
• Plasma Cell dyscrasia (bone marrow plasma cell <20%)	06	20.0
• Secondary Reactive Marrow	02	6.7
Serum protein electrophoresis		
• Monoclonal band (M band)	24	80.0
• Normal findings	06	20.0
Immunofixation electrophoresis (IFE)		
• IgG Kappa monoclonal protein	15	50.0
• IgG Lambda monoclonal protein	09	30.0
• IgA Kappa monoclonal protein	02	06.7
• IgM Kappa monoclonal protein	02	06.7
• Light change kappa monoclonal protein	02	06.7

Table 2: Monoclonal component absent in serum protein electrophoresis but present in serum immunofixation electrophoresis (n=30)

Serum protein electrophoresis	Serum immunoglobulin pattern				
	IgG Kappa monoclonal gammopathy (n=15)	IgG Lambda monoclonal gammopathy (n=9)	IgM Kappa monoclonal gammopathy (n=2)	IgA Kappa monoclonal gammopathy (n=2)	Light chain kappa monoclonal gammopathy (n=2)
Monoclonal protein (M band)					
Normal finding	14(93.3)	6(66.7)	02(100)	02(100)	0(0)
	01(6.7)	03(33.3)	0	0	2(100)

Clinical characteristics of monoclonal gammopathy patients were summarized. Among all patients, low backache and pallor were common in majority (80.0%) cases while fatigue and fever were present in 73.3% cases and 70.0% cases respectively. Among all patients, 7(23.3%) cases were hypertensive, 6(20.0%) cases were diabetic, 3(10.0%) cases were suffering from chronic kidney disease (CKD) with hypertension, 3(10.0%) cases had bronchial asthma, 1(3.3%) case was with hypertension and Diabetes Mellitus in each (Table 3).

Table 3: Clinical characteristics and Co-morbidities Associated with Monoclonal Gammopathy Patients (n= 30)

Variables	Frequency	Percent
Clinical features		
Pallor	24	80.0
Spine tenderness	15	50.0
Odema	12	30.0
Fatigue	22	73.3
Bone pain	24	80.0
Weight loss	18	60.0
Fever	21	70.0
Constipation	14	46.6
Cough	10	33.3
Co-morbidities associated with monoclonal gammopathy		
HTN	07	23.3
DM	06	20.0
CKD with HTN	03	10.0
Bronchial asthma	03	10.0
HTN with DM	01	03.3
Co-morbidity absent	10	33.3

HTN=Hypertension; CKD=Chronic Kidney Disease; DM=Diabetes mellitus

In IgG Kappa monoclonal gammopathy patients, renal insufficiency was present in 33.3% cases, hypercalcaemia in 40% cases, urinary BJP was detected in 26.7% cases (Table-4). In IgG lambda monoclonal gammopathy, renal insufficiency was present in 77.7% cases, hypercalcaemia in 44.4% cases and urinary BJP was present in 44.4% cases.

Table 4: Distribution of Biochemical Change in Different Immunoglobulin Pattern (monoclonal gammopathy)

Biochemical Change	Serum immunoglobulin pattern				
	IgG Kappa monoclonal gammopathy (n=15)	IgG Lambda monoclonal gammopathy (n=9)	IgM Kappa monoclonal gammopathy (n=2)	IgA Kappa monoclonal gammopathy (n=2)	Light chain kappa monoclonal gammopathy (n=2)
Renal insufficiency (S. creatinine >2.0 mg/dL)	5(33.3%)	7(77.7%)	0(0.0%)	2(100.0%)	2(100.0%)
Hypercalcaemia(11.0 mg/dL)	6(40.0%)	4(44.4%)	1(50.0%)	1(50.0%)	2(100.0%)
Bence-Jones protein (BJP)present	8(53.3%)	4(44.4%)	0(0.0%)	2(100.0%)	2(100.0%)

Table 5: Immunoglobulin pattern in different monoclonal gammopathies.

Pattern of monoclonal immunoglobulin (monoclonal gammopathy)	Diagnosis			
	Multiple myeloma	Smouldering multiple myeloma	MGUS	Kappa light chain multiple myeloma
IgG Kappa	11(36.6%)	2(6.7%)	2(6.7%)	0(0.0%)
IgG Lambda	6(20.0%)	0(0.0%)	3(10.0%)	0(0.0%)
IgM Kappa	2(6.7%)	0(0.0%)	0(0.0%)	0(0.0%)
IgA Kappa	2(6.7%)	0(0.0%)	0(0.0%)	0(0.0%)
Light chain kappa	0(0.0%)	0(0.0%)	0(0.0%)	2(6.7%)
Total (n=30)	21(70 %)	2(6.7%)	5(16.6)	2(6.7%)

Discussion

In this study was taken to study the clinical profile of monoclonal gammopathy cases and their immunoglobulin pattern in tertiary care referral centre. It was observed that monoclonal gammopathies predominantly occur in old age (mean age 57.13 ± 9.66 years) and a male dominant disease (Male: Female 1.72:1). Shaheen et al⁷ study also reported that, mean age of occurrence of monoclonal gammopathies is 58 years with a range of 23 to 86 years and male female ratio was 1.35:1. In addition, other studies from Asian countries also supports our findings^{8,9}. Anaemia observed among the monoclonal gammopathy patients in present study was also reported before by Talerman et al¹⁰ study, where they observed 74% of cases were having anaemia while Shaheen et al⁷ found haemoglobin below normal in 90% cases. The reason for anaemia can be either as a result of renal impairment or can be due to bone marrow failure because of marrow infiltration by myeloma cells⁹. In present study, monoclonal M-band was present in 80% cases while Yasseen et al¹¹ found M-band in 93.75% cases.

Though in a previous study¹² 56% common clinical presentation was bone related, we observed most common symptoms in our study were bone pain in 80.0% cases supported by similar study report by Kyle

et al¹³. In present study, fatigue was found in 73.3% cases, which was similar to study performed by Shaheen et al⁷. In present study, pallor was present in 80% cases though 56% and 65% was detected in other studies^{7,10}. Pallor indicates anaemia. In present study, the percentage of pallor (80%) was similar to the percentage of patients who were found to have hemoglobin level less than normal reference indicating anaemia. Hypertension and Diabetes mellitus was around 20% of co-morbidities associated with monoclonal gammopathy observed in current study which similar to the study performed by Fousad et al¹⁴. In the present study, out of 30 monoclonal gammopathy cases, M band identified in 80% cases by conventional serum protein electrophoresis whereas by the IFE method found the presence of M band in 100% cases. Tate et al¹⁵ also observed M band in 74.3%-87.0% cases by serum protein electrophoresis, however through IFE the detection increased to 97.4%. This occurs due to sensitivity and specificity of the IFE method¹⁶. It is known that majority of those missed M-proteins are in MGUS group which fall in the low risk of progression to Multiple myeloma. The presence of specific Immunoglobulin in M Band categories by immunofixation method. Majority (50%) of the cases under this study were IgG Kappa and 30% were IgG Lambda monoclonal protein, comprising total 80% of

the cases. Predominance of IgG monoclonal gammopathies such as 71.47%, 51.40% and 57% of the total cases was observed in different studies^{17,18,19} followed by IgA monoclonal gammopathies.

Several biochemical tests were performed in current study to see the level of serum creatinine, albumin and calcium and urinary Bence Jones protein. In 53.3% cases of monoclonal gammopathies, serum creatinine was detected >2 mg/dl indicating renal insufficiency which support the previous study findings^{9,13}. Lee et al²⁰ detected lambda chain myeloma as the highest risk (100.0%) of developing renal insufficiency. In present study though the sample size was too small, we also detected 100.0% renal insufficiency in the same group. This study shows urine for Bence Jones protein was present more than fifty percent of study population which was similar to study performed by Youinou et al¹⁸. Hypoalbuminaemia (<3.5 mg/dl) found in 70% of the monoclonal gammopathies patients observed in present study shows similarity of study done by Shaheen et al⁷.

Conclusion

This study shows monoclonal gammopathy occurs predominantly in male population at around sixth decade of life where fatigue and bone pain were most common symptoms and majority had spine tenderness on examination. Laboratory findings indicates that a large number of patients have been suffering from multiple myeloma.

References

1. Durie BG, Kyle RA, Belch A, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. *Hematol J* 2003;4:379-98
2. Guidelines Working Group of UK Myeloma Forum; British Committee for Standards in Haematology, British Society for Haematology. Guidelines on the diagnosis and management of AL amyloidosis. *Br J Haematol* 2004 ;125:681-00
3. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of tumours of Haematopoietic and lymphoid tissues. 4th ed. Lyon, France: International Agency for research on Cancer , 2008
4. Lee JH, Lee DS, Lee JJ, Chang YH, Jin JY, JoDY, et al. Multiple myeloma in Korea: Past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party. *Int J Hematol* 2010;92:52-7.
5. Huang SY, Yao M, Tang JL, Lee WC, Tsay W, Cheng AL, et al. Epidemiology of multiple myeloma in Taiwan: Increasing incidence for the past 25 years and higher prevalence of extramedullary myeloma in patients younger than 55 years. *Cancer* 2007;110:896-905
6. Bradwell AR, Mead GP, Carr-Smith HD. Serum Free Light Chain Analysis, 215 (The Binding Site, Ltd., Birmingham, UK, 2005)
7. Shaheen H, Ghangroo I, Malik I. Clinicopathological features and management of Pakistani patients with multiple myeloma. *J Pak Med Assoc.* 1999;49(10):233-37
8. Kim K, Lee JH, Kim JS, Min CK, Yoon SS, Shimizu K, et al. Clinical profiles of multiple myeloma in Asia - An Asian Myeloma Network study. *Am J Hematol* 2014;89:751-6
9. Kaur P, Shah BS, Baja P. Multiple myeloma: A clinical and pathological profile. *Gulf J Oncology* 2014;1:14-20
10. Talerman A. Clinico-Pathological study of multiple Myeloma in Jamaica, Pathology Department, University of the West Indies, Kingston, Jamaica, 1969;22(1):285-93
11. Yasseen KM, Kh. Elmeshhedany A, Al. Obidi DS. Skeletal Manifestations and Role of Dexa Study in 32 Patients with Multiple Myeloma, *The Iraqi Postgraduate Medical Journal*, 2007;6(4):307-13
12. Sridhar S, Dutta TK, Basu D. Clinical profile of multiple myeloma and effect of thalidomide based treatment on its outcome. *J Indian Med Assoc* 2011;109:880-2, 887-8
13. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. *Mayo Clin Proc* 2003;78:21-33
14. Fousad C, Gangadharan KV, Abdullah C, Narayan R et al. Clinical profile of multiple myeloma in south India. *Indian Journal of Medical and Paediatric Oncology*, 2018; 39:62-66
15. Tate J, Mollie P, Johnson R. Monoclonal Gammopathies-Clinical and Laboratory Issues. *Clin Biochem Rev* 2009;30(8):89-91
16. Katzmann JA, Stankowski-Drengler TJ, Kyle RA, Lockington KS, Snyder MR, Lust JA, et al. Specificity of Serum and Urine Protein Electrophoresis for the Diagnosis of Monoclonal Gammopathies. *Clinical Chemistry* 2010;56:12:1899-00
17. Riccaracci A, Ucci U, Luoni R, Castello A, Coci A, Magrini U, et al. Bone marrow biopsy in monoclonal gammopathies: correlations between pathological findings and clinical data. *J Clin Pathol* 1990;43:469-75
18. Youinou P, Le Goff P, Saleun JP, Jouquan J, Tymen G, Le Menn G. Monoclonal gammopathies. Critical review of 219 cases collected over 3 years. *Pathol Biol (Paris)*. 1977;25(8):517-21
19. Steingrimsdottir H, Haraldsdottir V, Olafsson I, Gudnason V, Ogmundsdottir HM. Monoclonal gammopathy: natural history studied with a retrospective approach. *Haematologica* 2007;92:1131-34
20. Lee LN, Jan IS, Tien HF, Lin JS, Lo SC, Cheng WC. Laboratory and clinical characterization of monoclonal gammopathy in Taiwanese. *J Formos Med Assoc.* 2002;101(2):91-07